Literature DB >> 22313962

A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis.

Karim Sacre1, Peter W Hunt, Priscilla Y Hsue, Ekaterina Maidji, Jeffrey N Martin, Steven G Deeks, Brigitte Autran, Joseph M McCune.   

Abstract

OBJECTIVE: HIV-infected individuals are at increased risk for myocardial infarction. Given observations that cytomegalovirus (CMV) infection, CMV-specific T cells, and CX3CR1 have each been associated with atherosclerosis, we hypothesized that CMV-induced T-cell immunopathology could contribute to HIV-associated atherosclerosis.
METHODS: We measured the expression of CX3CR1 on peripheral blood mononuclear cells and its association with carotid artery intima-media thickness (IMT) in 29 HIV-infected individuals and 48 uninfected controls. We analyzed the phenotype and specificity of CX3CR1(+)CD4(+) T cells, the production of CX3CL1 (the ligand of CX3CR1) by CMV-infected endothelial cells in vitro, and the migration of CD4(+) T cells induced by CX3CL1.
RESULTS: The progression of atherosclerosis in HIV-infected individuals, as assessed by longitudinal measurements of carotid IMT, was associated with a high frequency of CD4(+) T cells that express the chemokine receptor CX3CR1. Such CD4(+)CX3CR1(+) T cells were antigen-primed, produced high levels of pro-inflammatory cytokines, and composed the majority of the CMV-specific CD4(+) T cells. CMV-stimulated CD4(+) T cells were also found to induce the production of CX3CL1 (the ligand for CX3CR1) by human arterial endothelial cells, driving the transendothelial migration of pro-inflammatory CD4(+) T cells. Finally, we observed that CD4(+)CX3CR1(+) T cells could be localized to the coronary arterial wall in HIV disease.
CONCLUSION: HIV-associated atherosclerosis may be driven by a positive feedback pathway in which a high frequency of antigen-stimulated, CMV-specific CD4(+)CX3CR1(+) T cells induce endothelial cells to secrete CX3CL1, which itself drives progressive infiltration of the arterial wall by pro-inflammatory cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22313962      PMCID: PMC4155398          DOI: 10.1097/QAD.0b013e328351f780

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  29 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

2.  CD27 is required for generation and long-term maintenance of T cell immunity.

Authors:  J Hendriks; L A Gravestein; K Tesselaar; R A van Lier; T N Schumacher; J Borst
Journal:  Nat Immunol       Date:  2000-11       Impact factor: 25.606

3.  Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database.

Authors:  Madeleine Durand; Odile Sheehy; Jean-Guy Baril; Jacques Lelorier; Cécile L Tremblay
Journal:  J Acquir Immune Defic Syndr       Date:  2011-07-01       Impact factor: 3.731

4.  Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients.

Authors:  Victor Appay; Solène Fastenackels; Christine Katlama; Hocine Ait-Mohand; Luminita Schneider; Amélie Guihot; Michael Keller; Beatrix Grubeck-Loebenstein; Anne Simon; Olivier Lambotte; Peter W Hunt; Steven G Deeks; Dominique Costagliola; Brigitte Autran; Delphine Sauce
Journal:  AIDS       Date:  2011-09-24       Impact factor: 4.177

5.  Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease.

Authors:  D Moatti; S Faure; F Fumeron; M el-W Amara; P Seknadji; D H McDermott; P Debré; M C Aumont; P M Murphy; D de Prost; C Combadière
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

6.  In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells.

Authors:  M Grazia Revello; Fausto Baldanti; Elena Percivalle; Antonella Sarasini; Luciana De-Giuli; Emilia Genini; Daniele Lilleri; Nazarena Labò; Giuseppe Gerna
Journal:  J Gen Virol       Date:  2001-06       Impact factor: 3.891

Review 7.  Pathogenesis of HIV-associated cardiovascular complications.

Authors:  G Barbaro; S D Fisher; S E Lipshultz
Journal:  Lancet Infect Dis       Date:  2001-09       Impact factor: 25.071

Review 8.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection.

Authors:  Priscilla Y Hsue; Joan C Lo; Arlana Franklin; Ann F Bolger; Jeffrey N Martin; Steven G Deeks; David D Waters
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

10.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Authors:  Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

View more
  43 in total

Review 1.  HIV infection and immune activation: the role of coinfections.

Authors:  Afroditi Boulougoura; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

Review 2.  Infection and Stroke: an Update on Recent Progress.

Authors:  Eliza C Miller; Mitchell S V Elkind
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

3.  Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Authors:  Theodoros Kelesidis; Thuy Tien T Tran; James H Stein; Todd T Brown; Carlee Moser; Heather J Ribaudo; Michael P Dube; Robert Murphy; Otto O Yang; Judith S Currier; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

Review 4.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

Review 5.  The Sordid Affair Between Human Herpesvirus and HIV.

Authors:  Sara Gianella; Marta Massanella; Joel O Wertheim; Davey M Smith
Journal:  J Infect Dis       Date:  2015-03-06       Impact factor: 5.226

Review 6.  Cytomegalovirus and HIV: A Dangerous Pas de Deux.

Authors:  Sara Gianella; Scott Letendre
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

Review 7.  Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.

Authors:  Emma Kaplan-Lewis; Judith A Aberg; Mikyung Lee
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

Review 8.  Role of immune activation in progression to AIDS.

Authors:  Netanya S Utay; Peter W Hunt
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

Review 9.  Immune activation and cardiovascular disease in chronic HIV infection.

Authors:  Chris T Longenecker; Claire Sullivan; Jason V Baker
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

Review 10.  HIV-associated chronic immune activation.

Authors:  Mirko Paiardini; Michaela Müller-Trutwin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.